Biomarkers of Selenium Action in Prostate Cancer
Abstract
This study was designed to identify new, mechanistically relevant biomarkers of selenium responsiveness for use in intervention trials. We have completed our first aim which is to identify common molecular targets of different forms of selenium that are secretory using bioinformatics approaches and datasets of selenium-modulated transcripts and membrane bound and secretory proteins. 17 genes and 123 named unique genes that are membrane bound/secretory and upregulated by three or two forms of selenium respectively were selected. Out of these 140 genes, 15 were shown to be secretory by conventional methods according to published literature. In addition, we have determined the similarities and differences in global gene expression charges induced by methylseleninic acid (MSA) and selenomethionine (SM) in prostate cancer cells LNCaP. 2,336 and 2,165 unique genes showed expression changes at least 1.5 fold in at least 3 samples in response to SM and MSA respectively. 366 genes were statistically significantly differentially expressed between MSA and SM treated cells. At the same concentration, SM and MSA modulated press. However, they exert their effects on LACaP cells through both different and common molecular targets.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2005
- Accession Number
- ADA433948
Entities
People
- Hongjuan Zhao
Organizations
- Stanford University